Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd. (003220)

Market Closed
15 Jun, 06:30
KRX SM KRX SM
9,510. 00
+270
+2.9221%
270.92B Market Cap
- P/E Ratio
1,200% Div Yield
11,450 Volume
- Eps
9,240
Previous Close
Add Transaction
Day Range
9,400 9,510
Year Range
8,070 13,700
Want to track 003220 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

003220 closed today higher at ₩9,510, an increase of 2.9221% from yesterday's close, completing a monthly increase of 8.9347% or ₩780. Over the past 12 months, 003220 stock lost -20.1511%.
003220 is not paying dividends to its shareholders.
The last earnings report, released on May 13, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -270.8347%, based on the last three reports.
Daewon Pharmaceutical Co., Ltd. has completed 14 stock splits, with the recent split occurring on Mar 07, 2022.
The company's stock is traded on one exchange.

003220 Chart

People also search for

Hyundai Motor Co.
647,000
+6.5898%
Hyundai Motor Co. Ltd.
244,500
+4.9356%
Hyundai Motor Co. Ltd. Preferred
256,500
+6.2112%
Hyundai Motor Co., Ltd. Preferred
257,000
+6.639%
Kia Corporation
167,500
+0.4197%

Daewon Pharmaceutical Co., Ltd. (003220) FAQ

What is the stock price today?

The current price is ₩9,510.00.

On which exchange is it traded?

Daewon Pharmaceutical Co., Ltd. is listed on KRX SM.

What is its stock symbol?

The ticker symbol is 003220.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1,200%.

What is its market cap?

As of today, the market cap is 270.92B.

Has Daewon Pharmaceutical Co., Ltd. ever had a stock split?

Daewon Pharmaceutical Co., Ltd. had 14 splits and the recent split was on Mar 07, 2022.

Daewon Pharmaceutical Co., Ltd. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Mr. Seung-Ryel Baek CEO
KRX SM Exchange
KR7003220001 ISIN
KR Country
1,283 Employees
29 Dec 2025 Last Dividend
11 Feb 2019 Last Split
- IPO Date

Overview

Daewon Pharmaceutical Co., Ltd. is a renowned pharmaceutical entity based in Seoul, South Korea, established in 1958. The company specializes in the manufacturing and distribution of a wide range of medicines and medical supplies, primarily catering to the South Korean market. Their product line extends across various medical domains, including circulatory, respiratory, antibiotics, chemotherapy, and psychoneurosis medications. Daewon Pharmaceutical prides itself on its expansive global footprint, exporting products to about 40 countries across Asia, Central and South America, the Middle East, CIS, and Africa. The commitment to quality and innovation has positioned Daewon Pharmaceutical as a key player in the pharmaceutical industry.

Products and Services

  • Oramin-F Soft Cap

    A multivitamin product designed to support overall health and wellness. Oramin-F Soft Cap caters to individuals needing to supplement their daily vitamin intake.

  • Pelubi Tablet

    A Non-Steroidal Anti-Inflammatory Drug (NSAID) formulated for effective pain relief. Pelubi Tablets are typically prescribed for managing pain and inflammation associated with various conditions.

  • Freefol-MCT Inj.

    A microemulsion propofol utilized for its anti-exogenous infectious bacteria properties. Freefol-MCT Inj. is critical in medical settings for its efficacy in managing bacterial infections.

  • Megex-I Susp

    This medication is aimed at supplementing the subalimentation of cancer patients. Megex-I Susp provides essential nutrition support, addressing the unique needs of this patient population.

  • Trigel Susp

    A therapeutic suspension formulated for the treatment of gastritis and duodenal ulcers. Trigel Susp offers relief and promotes healing in patients suffering from these gastrointestinal conditions.

  • Renamezin Cap

    A spherical carbonaceous adsorbent designed specifically for patients with chronic kidney disease (CKD). Renamezin Cap helps in managing the symptoms and progression of CKD, offering a better quality of life for sufferers.

Contact Information

Address: 386 Cheonhodae-ro, Seoul, South Korea
Phone: 82 2 2204 7000